Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
HORSHAM, Pa., March 06, 2018 -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced today that its fourth quarter and fiscal 2017 financial results earnings call has been delayed to March 29th. The call has been delayed because additional time is required, due in part to an extended power outage at the Company’s Horsham, PA facility, to complete the company's review of certain accounting matters.
About STRATA Skin Sciences, Inc. (www.strataskinsciences.com)
STRATA Skin Sciences is a medical technology company focused on the therapeutic and aesthetic dermatology market. Its products include the XTRAC® laser and VTRAC® excimer lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions; the STRATAPEN® MicroSystem, marketed specifically for the intended use of micropigmentation; and NORDLYS, a multi-technology aesthetic laser device.
| Investor Contacts: | ||
| Frank McCaney, Chief Executive Officer STRATA Skin Sciences, Inc. 215-619-3200 [email protected] | Bob Yedid, Managing Director LifeSci Advisors, LLC 646-597-6989 [email protected] |
